Alpha-herpevirus assembly egress and viral particle heterogeneity

α-疱疹病毒装配出口和病毒颗粒异质性

基本信息

  • 批准号:
    8212020
  • 负责人:
  • 金额:
    $ 30.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-02-01 至 2015-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The neuroinvasive herpesviruses are a highly-prevalent group of the alpha-herpesvirus subfamily that includes the human pathogens: herpes simplex virus types 1 and 2 (HSV-1, HSV-2), and varicella zoster virus (VZV). An additional member of this group is a virus of veterinary significance, pseudorabies virus (PRV), which historically has provided models for studying viral pathogenesis. Despite the availability of the antiviral compound acyclovir, several severe forms of disease caused by these viruses remain prevalent in this country and worldwide. Infections associated with high rates of morbidity or mortality includes encephalitis, keratitis, shingles and disseminated infections in newborns. Novel strategies to interfere with the assembly and egress of these viruses could prove valuable to treatment of infections, yet much of the herpesvirus infectious cycle remains undefined. In this application we leverage our expertise in infectious clone mutagenesis and single viral particle fluorescence imaging methods to dissect viral structural composition in living-cells and extracellularly, and to address the molecular pathways guiding viral assembly and egress. New evidence is provided indicating that the very large herpesvirus tegument protein, VP1/2, is a key effector of viral assembly during distinct stages of assembly in the nucleus and cytoplasm of infected cells. This proposal is based on the hypothesis that herpesvirus assembly and egress are coupled processes that occur through a series of sequential steps both in the nucleus and cytoplasm of infected cells, and that each of these steps are affected in part by the VP1/2 protein. Our goal is to refine our understanding of these steps at the level of the protein interactions that contribute to the dynamics of viral egress. This proposal includes comparative studies of model viruses from the two neuroinvasive herpesviruses subgroups, the simplex viruses (represented by HSV-1) and the varicelloviruses (represented by PRV), to develop a comprehensive analysis of the properties of these viruses. PUBLIC HEALTH RELEVANCE: Neuroinvasive herpesviruses are the causative agents of a number of severe diseases including shingles, encephalitis, neonatal infections and herpes keratitis (the leading cause of infectious blindness in the USA and other industrialized nations). This proposal focuses on understanding the molecular mechanisms that underlie the assembly and egress of herpesvirus particles, with the long- term goal of identifying new targets for the intervention of disease progression.
描述(申请人提供):神经侵袭性疱疹病毒是阿尔法疱疹病毒亚家族中高度流行的一组病毒,包括人类病原体:单纯疱疹病毒1型和2型(HSV-1,HSV-2)和水痘带状疱疹病毒(VZV)。这个小组的另一个成员是具有兽医意义的伪狂犬病病毒(PRV),它历史上曾为研究病毒的发病机制提供模型。尽管有抗病毒化合物阿昔洛韦可用,但由这些病毒引起的几种严重形式的疾病仍然在该国和世界各地流行。与高发病率或死亡率相关的感染包括脑炎、角膜炎、带状疱疹和新生儿播散性感染。干扰这些病毒的组装和输出的新策略可能被证明对感染的治疗有价值,但疱疹病毒感染周期的大部分仍未确定。在这项应用中,我们利用我们在感染性克隆突变和单病毒颗粒荧光成像方法方面的专业知识来剖析活细胞和细胞外的病毒结构组成,并解决指导病毒组装和出口的分子途径。新的证据表明,非常大的疱疹病毒被膜蛋白VP1/2在感染细胞的细胞核和细胞质中组装的不同阶段是病毒组装的关键效应器。这一建议是基于这样的假设,即疱疹病毒的组装和出口是通过感染细胞的细胞核和细胞质中的一系列连续步骤发生的耦合过程,并且这些步骤中的每一步都部分受到VP1/2蛋白的影响。我们的目标是在蛋白质相互作用的水平上完善我们对这些步骤的理解,这些相互作用有助于病毒出口的动态。这项建议包括对神经侵袭性疱疹病毒的两个亚组--单纯疱疹病毒(以HSV-1为代表)和水痘病毒(以PRV为代表)的模型病毒进行比较研究,以开发对这些病毒特性的全面分析。 公共卫生相关性:神经侵袭性疱疹病毒是许多严重疾病的病原体,包括带状疱疹、脑炎、新生儿感染和疱疹角膜炎(在美国和其他工业化国家,疱疹是感染性失明的主要原因)。这项建议侧重于了解疱疹病毒颗粒组装和排出的分子机制,长期目标是确定干预疾病进展的新靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gregory Allan Smith其他文献

Gregory Allan Smith的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gregory Allan Smith', 18)}}的其他基金

An R2 non-neuroinvasive herpes simplex virus type 2 vaccine
R2 非神经侵袭性单纯疱疹病毒 2 型疫苗
  • 批准号:
    10698921
  • 财政年份:
    2023
  • 资助金额:
    $ 30.2万
  • 项目类别:
Dynamic interactions within alpha-herpesvirus virions and their impact on infection
α-疱疹病毒病毒粒子内的动态相互作用及其对感染的影响
  • 批准号:
    10042917
  • 财政年份:
    2020
  • 资助金额:
    $ 30.2万
  • 项目类别:
Neurotropic herpesvirus envelopment and microtubule-mediated transport
嗜神经性疱疹病毒包膜和微管介导的运输
  • 批准号:
    10585954
  • 财政年份:
    2017
  • 资助金额:
    $ 30.2万
  • 项目类别:
Neurotropic herpesvirus envelopment and microtubule-mediated transport
嗜神经性疱疹病毒包膜和微管介导的运输
  • 批准号:
    9884716
  • 财政年份:
    2017
  • 资助金额:
    $ 30.2万
  • 项目类别:
Neurotropic herpesvirus envelopment and microtubule-mediated transport
嗜神经性疱疹病毒包膜和微管介导的运输
  • 批准号:
    9331794
  • 财政年份:
    2017
  • 资助金额:
    $ 30.2万
  • 项目类别:
Alpha-herpevirus assembly egress and viral particle heterogeneity
α-疱疹病毒装配出口和病毒颗粒异质性
  • 批准号:
    8605151
  • 财政年份:
    2010
  • 资助金额:
    $ 30.2万
  • 项目类别:
Alpha-herpevirus assembly egress and viral particle heterogeneity
α-疱疹病毒装配出口和病毒颗粒异质性
  • 批准号:
    8414430
  • 财政年份:
    2010
  • 资助金额:
    $ 30.2万
  • 项目类别:
Alpha-herpevirus assembly egress and viral particle heterogeneity
α-疱疹病毒装配出口和病毒颗粒异质性
  • 批准号:
    8018068
  • 财政年份:
    2010
  • 资助金额:
    $ 30.2万
  • 项目类别:
Alpha-herpevirus assembly egress and viral particle heterogeneity
α-疱疹病毒装配出口和病毒颗粒异质性
  • 批准号:
    7890106
  • 财政年份:
    2010
  • 资助金额:
    $ 30.2万
  • 项目类别:
Alpha-herpesvirus assembly, egress and viral particle heterogeneity
α-疱疹病毒组装、流出和病毒颗粒异质性
  • 批准号:
    7878985
  • 财政年份:
    2009
  • 资助金额:
    $ 30.2万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 30.2万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.2万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 30.2万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.2万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 30.2万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 30.2万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.2万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 30.2万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 30.2万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.2万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了